RxDoctor Payments Data

Jedidiah Burack, MD

Internal Medicine · Brooklyn, NYNPI 1013984392

Payments from drug & device makers

$1,949in general payments, 2019–2025

Across 102 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$679
  • Gilead$372
  • Novo Nordisk$167
  • AstraZeneca$160
  • Johnson & Johnson$142
  • Merck$59
  • plus $369 from 14 others

What the payments were for

  • Food & beverage$1,949100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,949 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$53,540
Medicare patients
145
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala134$542,418
TriumeqAbacavir/Dolutegravir/Lamivudi100$445,754
JulucaDolutegravir/Rilpivirine28$111,329
EliquisApixaban118$105,490
GenvoyaElviteg/Cob/Emtri/Tenof Alafen23$90,567
DovatoDolutegravir Sodium/Lamivudine32$88,345
Enbrel SureclickEtanercept12$87,737
OzempicSemaglutide74$72,891
DescovyEmtricitabine/Tenofov Alafenam25$50,597
TivicayDolutegravir Sodium22$46,930
FarxigaDapagliflozin Propanediol47$44,550
CompleraEmtricita/Rilpivirine/Tenof Df13$43,324
JanuviaSitagliptin Phosphate36$31,666
LinzessLinaclotide50$29,970
EntrestoSacubitril/Valsartan32$29,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Juluca, Dovato, Tivicay$679$692,358182 claims
GileadBiktarvy, Genvoya, Descovy$372$683,583182 claims
PfizerEliquis$21$105,490118 claims
Novo NordiskOzempic, Rybelsus$167$91,56890 claims
Johnson & JohnsonComplera, Xarelto$142$61,79532 claims
AstraZenecaFarxiga, Lokelma, Symbicort$160$56,26472 claims
MerckJanuvia, Isentress$59$55,54349 claims
Boehringer IngelheimJardiance, Tradjenta$51$34,99036 claims
Lilly USA, LLCTrulicity, Mounjaro$26$33,41226 claims
AbbVieLinzess$32$29,97050 claims
NovartisEntresto$25$29,55232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →